| answer text |
<p>Alongside our G7 partners, the UK is committed to working internationally on efforts
to support our ambitious shared goal of vaccinating the world by the end of 2022.
This includes efforts to increase vaccine supply by working with suppliers to boost
manufacturing, and develop more sustainable approaches to support COVAX as well as
wider future pandemic preparedness.</p><p>Building vaccine manufacturing capacity
is a long term, capital intensive, and high risk endeavour that will require sustained
partnerships for supporting viable business models. We are working with the COVAX
Supply Chains and Manufacturing Task Force, multilateral, and industry partners to
expand quality and affordable vaccine supplies, smooth supply chains, support better
information sharing and match making to increase trusted partnerships for manufacturing.
The UK has funded McKinsey to scope opportunities for increasing vaccine manufacturing
in Africa, and supported the African Union's Africa Manufacturing summit in April
this year. We were also the largest funder of Coalition for Epidemic Preparedness
Innovations (CEPI) in 2020, which is leading work internationally to increase vaccine
manufacturing capacity.</p>
|
|
